As proof of concept, we demonstrated that vaccination of melanoma-bearing mice with antigen-pulsed LPS-treated p50−/− DC boosted antitumor immunity and inhibition of tumor growth, while silencing of p50 in human DC enhanced their ability to induce a more powerful Th1 activation. This evidence concerns the gene CD40 and melanoma.